H.C. Wainwright & Co., LLC ("HCW") announces a significant milestone, securing its #1 ranking for the 40th consecutive quarter in PlacementTracker’s Market League Tables by transaction volume. "This ...

Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Acumen Pharmaceuticals ...

HC Wainwright cut their FY2028 EPS estimates for shares of Gevo in a report released on Friday, March 28th. HC Wainwright ...

H.C. Wainwright adjusted the firm’s price target on BioLineRx (BLRX) to $26 from $9 and keeps a Buy rating on the shares after making ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $115 and keeps a Buy rating on the shares after the ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s shares closed last Friday at $0.50.

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...